• Celtaxys Inc., of San Francisco, said it started a Phase I study of CTX-4430, which is designed to block pro-inflammatory enzyme leukotriene A4 hydrolase. The repeat-dose study is aimed at evaluating the safety, tolerability and pharmacokinetics of the drug and will enroll 96 subjects.